PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28862770-7 2018 CONCLUSIONS: Both strategies alleviated symptoms in short term, but the patients treated with GS benefited more than those with placebo in long term, which may be due to the suppression of IL-1beta and IL-6 and the stimulation of TGF-beta. Glucosamine 94-96 transforming growth factor beta 1 Homo sapiens 230-238 31597574-0 2019 Glucosamine impedes transforming growth factor beta1-mediated corneal fibroblast differentiation by targeting Kruppel-like factor 4. Glucosamine 0-11 transforming growth factor beta 1 Homo sapiens 20-52 31597574-13 2019 CONCLUSION: These findings shed light on a novel mechanism by which GlcN suppresses TGF-beta1-induced fibroblast-to-myofibroblast differentiation through the upregulation of KLF4 expression. Glucosamine 68-72 transforming growth factor beta 1 Homo sapiens 84-93 21466783-9 2011 Study demonstrates that oral glucosamine doses that produce clinically relevant serum glucosamine concentrations can induce tissue TGFbeta1 and CTGF expression in vivo and provides a mechanistic rationale for reported beneficial effects of glucosamine therapy. Glucosamine 86-97 transforming growth factor beta 1 Homo sapiens 131-139 21457483-6 2011 RESULTS: Glucosamine reduced the surface levels of TGF-beta receptor and the ability of ARPE-19 cells to bind TGF-beta. Glucosamine 9-20 transforming growth factor beta 1 Homo sapiens 110-118 24072041-11 2013 KEY MESSAGE: Glucosamine-mediated attenuation of TGF-beta signaling ameliorates renal fibrosis in vivo TGF-beta1-induced fibrogenic action is reduced by glucosamine in vitro N-glycosylation of the type II TGF-beta receptor is suppressed by glucosamine Glucosamine-induced defective N-glycosylation of TbetaRII decreases TGF-beta signaling. Glucosamine 13-24 transforming growth factor beta 1 Homo sapiens 49-57 24072041-11 2013 KEY MESSAGE: Glucosamine-mediated attenuation of TGF-beta signaling ameliorates renal fibrosis in vivo TGF-beta1-induced fibrogenic action is reduced by glucosamine in vitro N-glycosylation of the type II TGF-beta receptor is suppressed by glucosamine Glucosamine-induced defective N-glycosylation of TbetaRII decreases TGF-beta signaling. Glucosamine 13-24 transforming growth factor beta 1 Homo sapiens 103-112 24072041-11 2013 KEY MESSAGE: Glucosamine-mediated attenuation of TGF-beta signaling ameliorates renal fibrosis in vivo TGF-beta1-induced fibrogenic action is reduced by glucosamine in vitro N-glycosylation of the type II TGF-beta receptor is suppressed by glucosamine Glucosamine-induced defective N-glycosylation of TbetaRII decreases TGF-beta signaling. Glucosamine 153-164 transforming growth factor beta 1 Homo sapiens 49-57 24072041-11 2013 KEY MESSAGE: Glucosamine-mediated attenuation of TGF-beta signaling ameliorates renal fibrosis in vivo TGF-beta1-induced fibrogenic action is reduced by glucosamine in vitro N-glycosylation of the type II TGF-beta receptor is suppressed by glucosamine Glucosamine-induced defective N-glycosylation of TbetaRII decreases TGF-beta signaling. Glucosamine 153-164 transforming growth factor beta 1 Homo sapiens 103-112 21466783-6 2011 Apparent threshold serum glucosamine (C(max)) concentration required to increase TGFbeta1 expression in cartilage was 10-20 muM. Glucosamine 25-36 transforming growth factor beta 1 Homo sapiens 81-89 21466783-9 2011 Study demonstrates that oral glucosamine doses that produce clinically relevant serum glucosamine concentrations can induce tissue TGFbeta1 and CTGF expression in vivo and provides a mechanistic rationale for reported beneficial effects of glucosamine therapy. Glucosamine 29-40 transforming growth factor beta 1 Homo sapiens 131-139 21466783-9 2011 Study demonstrates that oral glucosamine doses that produce clinically relevant serum glucosamine concentrations can induce tissue TGFbeta1 and CTGF expression in vivo and provides a mechanistic rationale for reported beneficial effects of glucosamine therapy. Glucosamine 86-97 transforming growth factor beta 1 Homo sapiens 131-139 21466783-10 2011 Induction of renal TGFbeta1 and CTGF mRNA suggests that potential sclerotic side-effects may occur following consumption of potent glucosamine preparations. Glucosamine 131-142 transforming growth factor beta 1 Homo sapiens 19-27 9831302-2 1998 Since we have found (Kolm-Litty et al., 1998) that glucosamine, similar to the PKC activator phorbol myristate acetate (PMA), mimicks high glucose-induced TGF-beta1 overexpression and subsequent matrix overproduction, the action of these agents on the translocation of PKC isoenzymes was studied in cultured mesangial cells. Glucosamine 51-62 transforming growth factor beta 1 Homo sapiens 155-164 9421478-2 1998 We tested if structural analogues of D-glucose may mimic the high glucose effect and found that D-glucosamine was strikingly more potent than D-glucose itself in enhancing the production of TGF-beta protein and subsequent production of the matrix components heparan sulfate proteoglycan and fibronectin in a time- and dose-dependent manner. Glucosamine 96-109 transforming growth factor beta 1 Homo sapiens 190-198 9421478-3 1998 D-Glucosamine also promoted conversion of latent TGF-beta to the active form. Glucosamine 0-13 transforming growth factor beta 1 Homo sapiens 49-57 18223258-9 2008 TGF-beta increased [(3)H]glucosamine incorporation into glycosaminoglycans by 180% and [(35)S]Met/Cys incorporation into proteoglycan core proteins by 35% with both effects completely inhibited by SB431542. Glucosamine 25-36 transforming growth factor beta 1 Homo sapiens 0-8 10922969-3 2000 Local overproduction of TGF-B could be secondary to a synthesis of diacylglycerol, polyols, or glucosamines. Glucosamine 95-107 transforming growth factor beta 1 Homo sapiens 24-29